EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy

Eman Wehbe iD, Thulashigan Sreeharan, Gaurav Sutrave, Jessica Bui iD, Cindy Lau iD, Jung Yeun Park, Indy Sandaradura iD, David Darley, Peter Macdonald, Samuel Milliken, Jiin Nyuk Fung, Graham Jones iD und 6 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag168 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Eman Wehbe und 17 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia. Hauptthemen laut MEDLINE: Voriconazole, Cytochrome P-450 CYP2C19, Antifungal Agents, Mycoses. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives CYP2C19 phenotype is a known contributor to the interpatient variability in voriconazole response. Alternative therapy is recommended for ultrarapid/rapid and poor metabolizers due to increased probability of subtherapeutic exposure and side effects, respectively. We aimed to evaluate whether CYP2C19 phenotype is associated with switching from voriconazole to alternative antifungal therapy, in settings where genetic results were not available at the time prescribing decisions were made.

Methods

A multicentre, retrospective observational study was conducted in three Australian hospitals. Patients who had previously taken voriconazole (from 1 May 2019 to 31 May 2024) were invited to undergo pharmacogenomic testing. Medical records were audited to compare switching decisions across patients with different CYP2C19 phenotypes. Differences in voriconazole exposure and voriconazole-related adverse effects were also explored.

Results

Among 194 patients, most were normal or intermediate metabolizers (69%); 21% were rapid, 7% ultrarapid, and 3% poor metabolizers (underpowered). Switching to alternative antifungal therapy (32%; 62/194) mainly occurred due to adverse effect incidence and was not associated with CYP2C19 phenotype (P = 0.9041). C-reactive protein levels were significantly higher in patients who switched therapy (P < 0.001). All ultrarapid metabolizers on standard voriconazole 400 mg/day had subtherapeutic concentrations and only those on higher doses (500–1200 mg/day) achieved therapeutic concentrations.

Conclusions

CYP2C19 phenotype was not predictive of switching, which is a multifactorial prescribing decision likely influenced by therapeutic drug monitoring, inflammation and clinical status. Our observations on voriconazole dosing and exposure support a complementary prescribing approach: pharmacogenomic testing to identify patients who require atypical voriconazole dosing regimens and subsequent therapeutic drug monitoring to guide dose adjustments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VoriconazoleCytochrome P-450 CYP2C19Antifungal AgentsMycosesHumansFemaleRetrospective StudiesMaleMiddle AgedPhenotypeAgedAdultAustraliaPharmacogenomic Testing

Substanzen

VoriconazoleCytochrome P-450 CYP2C19Antifungal AgentsCYP2C19 protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
  • Department of Pharmacy, Westmead Hospital, Sydney, NSW 2145, Australia.
  • Westmead Institute for Medical Research, University of Sydney, Sydney, NSW 2145, Australia.
  • Department of Pharmacy, Royal North Shore Hospital, Sydney, NSW 2065, Australia.
  • Department of Pharmacy, St Vincent's Hospital, Sydney, NSW 2010, Australia.
  • Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, NSW 2145, Australia.

ORCID-Profile: Eman Wehbe, Jessica Bui, Cindy Lau, Indy Sandaradura, Graham Jones, Jan-Willem C Alffenaar, Sophie L Stocker

Förderung

  • Gilead Sciences

Zitieren

APA

Wehbe, E., Sreeharan, T., Sutrave, G., Bui, J., Lau, C., Park, J. Y., Sandaradura, I., Darley, D., Macdonald, P., Milliken, S., Fung, J. N., Jones, G., Kizny Gordon, A., Kliman, D., Lu, C. Y., Marriott, D., Alffenaar, J. C., & Stocker, S. L. (2026). Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag168

Vancouver

Wehbe E, Sreeharan T, Sutrave G, Bui J, Lau C, Park JY, et al. Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag168

BibTeX
@article{Wehbe2026,
  author = {Wehbe, Eman and Sreeharan, Thulashigan and Sutrave, Gaurav and Bui, Jessica and Lau, Cindy and Park, Jung Yeun and Sandaradura, Indy and Darley, David and Macdonald, Peter and Milliken, Samuel and Fung, Jiin Nyuk and Jones, Graham and Kizny Gordon, Alice and Kliman, David and Lu, Christine Y and Marriott, Deborah and Alffenaar, Jan-Willem C and Stocker, Sophie L},
  title = {Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag168}
}
Kostenlos starten →